New technique developed at Washington University in St. Louis uses blood test
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.
Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a groundbreaking, proof-of-concept technique that allows biomarkers from a brain tumor to pass through the tough blood-brain barrier into a patient’s blood using noninvasive focused ultrasound and some tiny bubbles, potentially eliminating the need for a surgical biopsy.
Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and of radiation oncology in the School of Medicine, said while researchers have already learned how to get a drug through the blood-brain barrier into the brain via the bloodstream, no one — until now — has found a way to release tumor-specific biomarkers — in this case, messenger RNA (mRNA)— from the brain into the blood.
“I see a clear path for the clinical translation of this technique,” said Chen, an expert in ultrasound technology. “Blood-based liquid biopsies have been used in other cancers, but not in the brain. Our proposed technique may make it possible to perform a blood test for brain cancer patients.”
The blood test would reveal the amount of mRNA in the blood, which gives physicians specific information about the tumor that can help with diagnosis and treatment options.
Results of the study, which blends imaging, mechanobiology, genomics, immunology, bioinformatics, oncology, radiology and neurosurgery, are published in Scientific Reports April 26, 2018.
Chen; Leuthardt, professor of neurological surgery in the School of Medicine; and researchers from the Schools of Engineering & Applied Science and of Medicine, tested their theory in a mouse model using two different types of the deadly glioblastoma brain tumor. They targeted the tumor using focused ultrasound, a technique that uses ultrasonic energy to target tissue deep in the body without incisions or radiation. Similar to a magnifying glass that can focus sunlight to a tiny point, focused ultrasound concentrates ultrasound energy to a tiny point deep into the brain.
Once they had the target — in this case, the brain tumor — researchers then injected microbubbles that travel through the blood similar to red blood cells. When the microbubbles reached the target, they popped, causing tiny ruptures of the blood-brain barrier that allows the biomarkers from the brain tumor to pass through the barrier and release into the bloodstream. A blood sample can determine the biomarkers in the tumor.
This technique could lead to personalized medicine.
“In many ways this has been a holy grail for brain tumor therapy,” Leuthardt said. “Having the ability to monitor the changing molecular events of the tumor in an ongoing way allows us to not only better diagnose a tumor in the brain, but to follow its response to different types of treatment.”
“Once the blood-brain barrier is open, physicians can deliver drugs to the brain tumor,” Chen said. “Physicians can also collect the blood and detect the expression level of biomarkers in the patient. It enables them to perform molecular characterizations of the brain tumor from a blood draw and guide the choice of treatment for individual patients.”
In addition, Gavin Dunn, MD, assistant professor of neurosurgery, a co-author and leader in cancer immunobiology, plans to use the technique with immunotherapy, which offers precision treatment that targets specific biomarkers in the brain.
“This noninvasive focused ultrasound-enabled liquid biopsy technique can be useful for long-term monitoring of brain cancer treatment response, where repeated surgical tissue biopsies may not be feasible,” Chen said. “Meanwhile, variations within tumors pose a significant challenge to cancer biomarker research. Focused ultrasound can precisely target different locations of the tumor, thereby causing biomarkers to be released in a spatially-localized manner and allow us to better understand the spatial variations of the tumor and develop better treatment.”
The team continues to work to refine the process. The future will require integration with advanced genomic sequencing and bioinformatics to enable even more refined diagnostics. These efforts are being led by co-authors Allegra Petti, assistant professor of medicine, and Xiaowei Wang, associate professor of radiation oncology.
“Our ongoing work is to optimize the technique and evaluate its sensitivity and safety,” Chen said.
Learn more: Noninvasive brain tumor biopsy on the horizon
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Strategic Evaluation of Precision Medicine: Country Analysis for Emerging Opportunities on September 18, 2018 at 12:53 pm
which have approximately doubled during the past five years and are expected to increase by 30% during the next three years.Approximately 69% of drug development during the ensuing five years is predi... […]
- Personalized Medicine in Prostate Cancer: Now More Precise on September 18, 2018 at 12:30 pm
Over the past decade, we have witnessed an explosion of molecular testing in the urology world that will help us better diagnose and manage prostate cancer across the spectrum of the disease. All of u... […]
- Software could lead to personalized leukemia treatments on September 18, 2018 at 11:06 am
Early findings from a new study could help in the development of immune-based treatments personalized to people with acute myeloid ... an assistant professor in the School of Medicine division of hema... […]
- Advanced Diagnostics for Personalized Medicine on September 14, 2018 at 6:21 am
For most of the 20th century all women with breast cancer received similar treatment. Therapy has since become more individualized: breast cancers are now divided into subtypes and treated accordingly ... […]
- Expert Explores Emerging Role of Personalized Medicine in HCC Treatment on September 14, 2018 at 6:14 am
Updates to the European Association for the Study of the Liver (EASL) clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma (HCC), explained Fa... […]
- Cancer Biomarkers Market is Forecast to Reach US$27.63 Billion by 2025; Rising Focus on Personalized Medicine to Accelerate Growth - TMR on September 14, 2018 at 4:05 am
The global cancer biomarkers market has been growing at a fast pace, owing to the research and development activities. The developing economies hold promising growth opportunities for the market playe... […]
- If you want personalized medicine, we’ll need to know what time it is in your liver on September 12, 2018 at 3:00 pm
Stop! It's body clock time. Back in 1960, researchers discovered that a specific toxin, given to a mouse at one time of the day, would kill it. Administer the same poison at a different time, and the ... […]
- InformedDNA Selected to Provide Genetic Counseling to Participants in Coriell Institute’s Personalized Medicine Collaborative Research Study on September 12, 2018 at 7:48 am
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--InformedDNA ®, the nation's largest independent provider of expert genetics services, has been selected by the Coriell Institute for Medical Research to provide ... […]
- Following the tumor DNA trail to crack the secrets of personalized medicine on September 10, 2018 at 10:53 am
Paris, France, 10 September 2018 - Individualised therapies that target the specific genetic features of tumours have the potential to transform cancer diagnosis, treatment and care. However, several ... […]
via Bing News